Article
Medicine, General & Internal
Alejandra Orozco Guillen, Virgilia Soto Abraham, Bernardo Moguel Gonzalez, Giorgina Barbara Piccoli, Magdalena Madero
Summary: IgA nephropathy is rarely associated with primary podocytopathy and has not been reported in pregnancy, mainly due to the infrequent use of kidney biopsy during pregnancy. We report a case of IgA nephropathy in a pregnant woman, which was timely diagnosed and successfully treated, resulting in a healthy baby and good maternal outcome.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Immunology
Ibrahim Batal, Pascale Khairallah, Astrid Weins, Nicole K. Andeen, Michael B. Stokes
Summary: Primary focal segmental glomerulosclerosis (FSGS) is a disease characterized by diffuse podocyte foot process effacement and nephrotic syndrome. It can recur after transplantation and is associated with immunogenetic factors. This study retrospectively investigated a cohort of kidney allograft recipients with primary FSGS and found a higher frequency of HLA-A30 antigen in patients with primary FSGS compared to healthy controls and deceased kidney donors. The study also revealed an association between donor HLA-A30 and recurrent FSGS in transplant patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Xiaokang Wang, Jingqian Zhao, Yuanqing Li, Jiaoyu Rao, Gengrui Xu
Summary: Proteinuria and nephrotic syndrome are symptoms of kidney diseases caused by direct or indirect damage to podocytes. Inflammation plays a crucial role in the development and progression of diabetic nephropathy, the leading cause of end-stage renal disease worldwide. The impact of podocyte damage on metabolic and inflammatory disorders has been documented. Epigenetic and endoplasmic reticulum stress are also observed in diabetic nephropathy. Targeting inflammation pathway and endoplasmic reticulum stress in podocytes may offer potential therapies to prevent the progression of diabetic nephropathy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Fang Yu, Xuejing Zhu, Shuguang Yuan, Xiaojun Chen, Zheng Li, Zhong Qu, Hong Liu, Lin Sun, Fuyou Liu
Summary: This study found that S lesion >= 25% is associated with a more rapid decline in glomerular filtration rate and a lower rate of complete remission of proteinuria, even when adjusted for multiple clinicopathological variables, compared to the S1a group (all p values <0.05). Patients with S lesion >= 25% also had a higher proportion of glomeruli with T lesion and crescents. This suggests that IgAN patients with S lesion >= 25% are at increased risk of poor renal outcomes, even with immunosuppressive therapy.
ANNALS OF MEDICINE
(2021)
Article
Biology
Keiichiro Matoba, Yusuke Takeda, Yosuke Nagai, Kensuke Sekiguchi, Rikako Ukichi, Hiroshi Takahashi, Daisuke Aizawa, Masahiro Ikegami, Toshiaki Tachibana, Daiji Kawanami, Yasushi Kanazawa, Tamotsu Yokota, Kazunori Utsunomiya, Rimei Nishimura
Summary: ROCK2 is activated in diabetic models and patients, but its deletion in podocytes provides protection against kidney injury by rescuing PPAR alpha signaling and fatty acid metabolism. Loss of podocytes is a common feature in diabetic renal injury, and ROCK2 plays a critical role in this process. The findings suggest that ROCK2 could be a potential target for the treatment of diabetic podocytopathy.
COMMUNICATIONS BIOLOGY
(2022)
Article
Medicine, General & Internal
Camille Cohen, Severine Coulon, Kanit Bhukhai, Antoine Neuraz, Michael Dussiot, Guillemette Fouquet, Marie-Benedicte Le Stang, Martin Flamant, Francois Vrtovsnik, Aurelie Hummel, Bertrand Knebelmann, Laurent Mesnard, Eric Rondeau, Thiago T. Maciel, Fabrizia Favale, Nicole Casadevall, Thao Nguyen-Khoa, Stephane Moutereau, Christophe Legendre, Marc Benhamou, Renato C. Monteiro, Olivier Hermine, Khalil El Karoui, Ivan C. Moura
Summary: The involvement of IgA1 in unexplained polycythemia/erythrocytosis (PE) of IgA nephropathy (IgAN) patients was evaluated in this study. It was found that IgA1 plays a role in regulating erythropoiesis and elevated IgA1 levels increase the sensitivity of erythroid progenitors to Epo.
Review
Immunology
Yoshihito Nihei, Hitoshi Suzuki, Yusuke Suzuki
Summary: Immunoglobulin A (IgA) is the most abundant isotype of antibodies that plays a key role in defending against pathogens at mucosal surfaces. Although considered non-inflammatory, IgA can also cause diseases such as IgA nephropathy and IgA vasculitis.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Medicine, General & Internal
Evangeline Pillebout
Summary: Many authors have suggested that IgA Vasculitis and IgA Nephropathy may be two different clinical manifestations of the same disease, but larger clinical studies are needed to explore further. Limited studies have been conducted on these two diseases, and therapeutic trials often exclude patients with both conditions.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Genetics & Heredity
Michaela Stippel, Korbinian M. Riedhammer, Barbel Lange-Sperandio, Michaela Gessner, Matthias C. Braunisch, Roman Gunthner, Martin Bald, Miriam Schmidts, Peter Strotmann, Velibor Tasic, Christoph Schmaderer, Lutz Renders, Uwe Heemann, Julia Hoefele
Summary: This study investigated the presence of skeletal anomalies as an extrarenal manifestation in individuals with hereditary podocytopathies, ciliopathies or CAKUT, finding that 12% of the cohort presented with both kidney disease and additional skeletal phenotypes. Pathogenic variants in known disease-associated genes were identified in 63% of these cases, highlighting the genetic heterogeneity and clinical variability of hereditary nephropathies.
FRONTIERS IN GENETICS
(2021)
Article
Medicine, Research & Experimental
Negin Farzamikia, Behzad Baradaran, Soroush Mostafavi, Elham Ahmadian, Seyed Mahdi Hosseiniyan Khatibi, Sepideh Zununi Vahed, Mohammadreza Ardalan
Summary: Microparticles are vesicles released into the extracellular environment derived from cell plasma membranes, facilitating intercellular communication through the transfer of various lipids, cytosolic proteins, RNA, and microRNAs. The progression of diseases can affect the composition and function of these cell-derived particles, with podocyte injury playing a significant role in the pathophysiology of various glomerular diseases including IgA nephropathy.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Urology & Nephrology
Xue Zhang, Jicheng Lv, Pan Liu, Xinfang Xie, Manliu Wang, Dan Liu, Hong Zhang, Jing Jin
Summary: Poly-IgA immune complex formation and glomerular deposition play a key role in IgA nephropathy, and a novel ELISA method using recombinant CD89 for detecting these complexes was successfully established. Levels of poly-IgA were significantly higher in IgA nephropathy patients compared to healthy controls and non-IgA nephropathy controls. The poly-IgA index was associated with kidney function and response to treatment, showing good discrimination between IgA nephropathy and healthy controls.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Pediatrics
Nan Zhou, Hui Wang, Xin-yu Wang, Ye-ping Jiang, Qian Fu, Ying Liang, Guo-shuang Feng
Summary: We analyzed the demographic and clinical characteristics of children with immunoglobulin A (IgA) nephropathy using data in the first pages of electronic health records. This is a large sample, multi-center study. The incidence of IgA nephropathy in males increased gradually with age. Age was an important factor affecting CKD. The disease was related to environment and economic status.
PEDIATRIC RESEARCH
(2023)
Article
Medicine, General & Internal
Won Jung Choi, Yu A. Hong, Ji Won Min, Eun Sil Koh, Hyung Duk Kim, Tae Hyun Ban, Young Soo Kim, Yong Kyun Kim, Seok Joon Shin, Seok Young Kim, Young Ok Kim, Chul Woo Yang, Yoon-Kyung Chang
Summary: This study revealed a correlation between hyperuricemia and the histopathological severity of IgAN, with a stronger association observed in female patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Barbara Moszczuk, Natalia Krata, Witold Rudnicki, Bartosz Foroncewicz, Dominik Cysewski, Leszek Paczek, Beata Kaleta, Krzysztof Mucha
Summary: This study investigates osteopontin (OPN) as a potential biomarker in nephrology. Using machine learning, urinary OPN levels were found to accurately differentiate between immunoglobulin A nephropathy (IgAN) and other glomerulopathies (GNs). However, the discrimination of membranous nephropathy (MN) and lupus nephritis (LN) was less effective. OPN appears to be a valuable biomarker for identifying IgAN patients and should be further validated in future studies.
Article
Urology & Nephrology
Shuangshuang Zhu, Xiaoting Liu, Shuling Yue, Bei Luo, Zhen Song, Xiaomeng Xu, Lin Wang, Xiaotao Hou, Kongshan Li, Qiming Liang, Zheya Zhou, Wenfang Chen, Lei Zheng
Summary: This study investigated the prevalence and clinicopathological features of segmental membranous glomerulopathy (SMGN) in adults. The results showed that SMGN is a relatively rare pathological type, mainly occurring in females with a median age of 41.5 years. 33.1% of patients had full nephrotic syndrome, absence of PLA2R and THSD7A, 43.0% were NELL1-positive, and mainly stage I or II membranous nephropathy (MN) alterations (83.8%).
Article
Transplantation
Haresh Selvaskandan, Izabella Pawluczyk, Jonathan Barratt
Summary: RNA interference (RNAi) is a widely present and important regulatory process in all organisms, modulating gene transcription and post-transcriptional processing. microRNAs (miRNAs) can regulate multiple genes within a cell, and multiple miRNAs can regulate expression of the same gene, adding complexity to gene expression regulation. miRNAs and other RNAi approaches have been used for basic science research and targeted therapeutics. This review focuses on the potential of miRNAs as biomarkers and novel therapeutics for glomerular disease.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Genetics & Heredity
Nzar A. A. Shwan, Eric C. Moise, Paula E. Necsoiu, Amy J. Farr, Daniel P. Gale, Jonathan Barratt, John A. L. Armour
Summary: In this study, the researchers investigated the association between DEFA1A3 copy number variation (CNV) and IgA nephropathy. They measured DEFA1A3 copy number in UK family trios with an affected offspring and used population distributions to infer segregation in trios. The researchers observed some evidence for over- and undertransmission of specific haplotypes, but these effects were not statistically significant after correction for multiple testing.
ANNALS OF HUMAN GENETICS
(2023)
Article
Urology & Nephrology
Jonathan Barratt, Richard Lafayette, Jens Kristensen, Andrew Stone, Daniel Cattran, Jurgen Floege, Vladimir Tesar, Hernan Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Brad H. Rovin
Summary: The clinical trial (NefIgArd) of a novel targeted-release formulation of oral budesonide (Nefecon) for the treatment of IgA nephropathy (IgAN) demonstrated significant improvements in proteinuria and glomerular filtration rate, with good tolerability.
KIDNEY INTERNATIONAL
(2023)
Article
Medicine, General & Internal
William G. Herrington, Natalie Staplin, Christoph Wanner, Jennifer B. Green, Sibylle J. Hauske, Jonathan R. Emberson, David Preiss, Parminder Judge, Kaitlin J. Mayne, Sarah Y. A. Ng, Emily Sammons, Doreen Zhu, Michael Hill, Will Stevens, Karl Wallendszus, Susanne Brenner, Alfred K. Cheung, Zhi-Hong Liu, Jing Li, Lai Seong Hooi, Wen Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Cherney, Aldo P. Maggioni, Roberto Pontremoli, Rajat Deo, Shinya Goto, Xavier Rossello, Katherine R. Tuttle, Dominik Steubl, Michaela Petrini, Dan Massey, Jens Eilbracht, Martina Brueckmann, Martin J. Landray, Colin Baigent, Richard Haynes
Summary: Empagliflozin therapy reduces the risk of disease progression or cardiovascular death in patients with chronic kidney disease.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Urology & Nephrology
Malak Ghaddar, Jonathan Barratt, Sean J. Barbour
Summary: The use of corticosteroids to treat IgA nephropathy has been controversial. Recent trials have shown that a reduced dose of methylprednisolone can reduce the risk of kidney damage and proteinuria in patients with IgAN. The targeted-release budesonide has also been effective in reducing short-term proteinuria. More targeted therapies with better safety profiles are being investigated.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
(2023)
Letter
Urology & Nephrology
Jonathan Barratt, Brad H. Rovin
KIDNEY INTERNATIONAL
(2023)
Editorial Material
Urology & Nephrology
Chee Kay Cheung, Jonathan Barratt
KIDNEY INTERNATIONAL
(2023)
Letter
Urology & Nephrology
Jonathan Barratt, Brad H. Rovin
KIDNEY INTERNATIONAL
(2023)
Article
Multidisciplinary Sciences
Janev Fehmi, Alexander Davies, Marilina Antonelou, Stephen Keddie, Sonja Pikkupeura, Luis Querol, Emilien Delmont, Andrea Cortese, Diego Franciotta, Staffan Persson, Jonathan Barratt, Ruth Pepper, Filipa Farinha, Anisur A. Rahman, Diana B. Canetti, Janet Gilbertson, Nigel Rendell, Aleksandar Radunovic, Thomas M. Minton, Geraint S. Fuller, Sinead R. Murphy, Aisling Carr, Mary Reilly, Filip E. Eftimov, Luuk Wieske, Charlotte Teunissen, Ian S. D. D. Roberts, Neil Ashman, Alan Salama, Simon Rinaldi
Summary: Membranous glomerulonephritis (MGN) is a common cause of nephrotic syndrome, and an association between anti-contactin-1 (CNTN1)-mediated neuropathies and MGN has been suggested. This study investigated the association between CNTN1 antibodies and clinical features of patients with immune-mediated neuropathies and MGN. It was found that CNTN1 antibodies were present in patients with immune-mediated neuropathy and concurrent MGN, and CNTN1-containing immune complexes were found in the renal glomeruli of these patients, suggesting CNTN1 as a common target for autoantibody-mediated pathology in MGN.
Article
Multidisciplinary Sciences
Yujie Zhu, Mingchao Zhang, Weiran Wang, Shuang Qu, Minghui Liu, Weiwei Rong, Wenwen Yang, Hongwei Liang, Caihong Zeng, Xiaodong Zhu, Limin Li, Zhihong Liu, Ke Zen
Summary: Reduction of renal tubular cell PNPT1 causes renal tubular translation arrest and atrophy, which leads to tubular injury. Increasing PNPT1 expression can alleviate tubular injury.
NATURE COMMUNICATIONS
(2023)
Article
Urology & Nephrology
Jonathan Barratt, Brad Rovin, Muh Geot Wong, Charles E. Alpers, Stewart Bieler, Ping He, Jula Inrig, Radko Komers, Hiddo J. L. Heerspink, Alex Mercer, Irene L. Noronha, Jai Radhakrishnan, Michelle N. Rheault, William Rote, Howard Trachtman, Hernan Trimarch, Vlado Perkovic, PROTECT Investigators
Summary: The PROTECT trial is a multicenter, international study evaluating the efficacy and safety of sparsentan versus irbesartan in IgA nephropathy patients. Baseline characteristics of enrolled patients are described and compared to other relevant studies. The results will provide important characterization of the treatment effect in IgA nephropathy patients at high risk of kidney failure.
KIDNEY INTERNATIONAL REPORTS
(2023)
Article
Urology & Nephrology
Daisuke Koya, Stefan D. Anker, Luis M. Ruilope, Peter Rossing, Zhihong Liu, Byung Wan Lee, Chien-Te Lee, Charlie Scott, Peter Kolkhof, Robert Lawatscheck, Lili Wang, Amer Joseph, Bertram Pitt
Summary: This study found that finerenone significantly improved cardiorenal outcomes in Asian patients, with similar benefits seen in non-Asian patients as well. The safety profile of finerenone was consistent across subgroups.
AMERICAN JOURNAL OF NEPHROLOGY
(2023)
Article
Medicine, General & Internal
Michelle N. Rheault, Charles E. Alpers, Jonathan Barratt, Stewart Bieler, Pietro Canetta, Dong-Wan Chae, Gaia Coppock, Ulysses Diva, Loreto Gesualdo, Hiddo J. L. Heerspink, Jula K. Inrig, Gianna M. Kirsztajn, Donald Kohan, Radko Komers, Laura A. Kooienga, Kenneth Lieberman, Alex Mercer, Irene L. Noronha, Vlado Perkovic, Jai Radhakrishnan, William Rote, Brad Rovin, Vladimir Tesar, Hernan Trimarchi, James Tumlin, Muh Geot Wong, Howard Trachtman, DUPRO Steering Comm, DUPLEX Investigators
Summary: In the treatment of FSGS, sparsentan showed a better reduction in proteinuria compared to irbesartan. However, there were no significant differences in eGFR slope between the two groups at 108 weeks. Both sparsentan and irbesartan demonstrated similar safety profiles.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Sandra A. Lewis, Kevin J. Carroll, Todd Devries, Jonathan Barratt
Summary: Random coefficient (RC) models are commonly used in clinical trials to estimate the rate of change over time in longitudinal data. This paper provides calculation methods, with practical examples, for determining conditional power (CP) at an interim analysis for a RC model with longitudinal data.
PHARMACEUTICAL STATISTICS
(2023)
Meeting Abstract
Urology & Nephrology
David Pitcher, Fiona Braddon, Bruce Hendry, Alex Mercer, Kate Osmaston, Moina Saleem, Retha Steenkamp, A. Neil Turner, Kaijun Wang, Jonathan Barratt, Daniel Gale
AMERICAN JOURNAL OF KIDNEY DISEASES
(2023)